文献速递细菌感染、耐药与抗菌药物

抗菌与非抗菌产品监管审批特征比较(1984-2018):FDA灵活性评估

Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilities.
PubMed 文献 · Lancet Infect Dis · 2020-06-02

该研究分析了1984至2018年间FDA批准的1065种新药和生物制品,比较抗菌与非抗菌产品在孤儿药法案、快速通道、优先审评、加速批准和突破性疗法等项目的使用情况及临床研发和审评时间。结果显示抗菌产品更常使用优先审评、快速通道和加速批准,较少获得孤儿药认定,且从IND申请到批准的中位时间更短。

要点

  • 抗菌产品比非抗菌产品更常使用优先审评、快速通道和加速批准。
  • 抗菌产品从IND申请到批准的中位时间短于非抗菌产品。
  • 无证据表明抗菌产品在美国监管审批过程中比非抗菌产品更耗时。

核心结论

  • 除孤儿药法案资格外,抗菌产品至少与非抗菌产品同样频繁地使用快速临床测试和审评项目。
  • 无证据支持抗菌产品在美国监管审批过程中比非抗菌产品开发更耗时的说法。

研究设计与样本

  • 研究分析了1984年至2018年间美国FDA批准的全部1065种新药和生物制品。
  • 记录了每种药物对孤儿药法案、快速通道、优先审评、加速批准和突破性疗法项目的使用情况,以及IND申请、NDA申请和批准日期,用于计算临床研发和审评时间。

主要发现

  • 抗菌产品有178种(17%),非抗菌产品有887种。

临床怎么用

  • 抗菌药物研发可积极利用FDA的快速通道、优先审评和加速批准等灵活性监管途径。
  • 临床医生和研究者应了解抗菌药物审批时间可能不比非抗菌药物更长,有助于推动新药研发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance is of growing concern. To encourage development of new treatments, some commentators have suggested regulators exercise increased flexibility on the clinical evidence required for approval. We examined all 1065 new drugs and biologics approved by the US Food and Drug Administration between 1984 and 2018 and recorded each drug's use of the Orphan Drug Act, fast-track, priority review, accelerated approval, and breakthrough therapy programmes, as well as dates of investigational new drug application, new drug application, and new drug approval, which were used to calculate clinical development and review times. There were 178 (17%) antimicrobial products, which were more likely than non-antimicrobial products to benefit from priority review (103 [58%] of 178 vs 402 [45%] of 887, p=0·0023), fast-track designation (58 [37%] of 157 vs 151 [19%] of 814], p<0·001), and accelerated approval (23 [18%] of 129 vs 67 [9%] of 711, p=0·0046), and less likely to have Orphan Drug Act designation (25 [14%] of 178 vs 267 [30%] of 887, p<0·0001). Median time from investigational new drug application to approval was shorter for antimicrobial than for non-antimicrobial drugs (5·9 years [IQR 4·6-7·3] vs 7·6 years [IQR 5·7-10·2], p<0·001). Except for Orphan Drug Act status, expedited clinical testing and review programmes have been used at least as frequently for antimicrobial products as for non-antimicrobial drugs. No evidence supported claims that antimicrobial progress through the regulatory approval process in the USA is more time-consuming than non-antimicrobial development.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Darrow JJ, Najafzadeh M, Stefanini K, et al. Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilities. Lancet Infect Dis. 2020. PMID: 32502431. doi:10.1016/S1473-3099(20)30197-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。